Mental healthcare company focusing on speeding patient access to evidence-based innovation in mental health COMPASS Pathways Plc. (NASDAQ: CMPS) announced having secured patent approval from United States Patent and Trademark Office (UPTSO) for its claims covering its Form A hydrate psilocybin.
The Form A hydrate is a distinct from the anhydrate psilocybin of which COMPASS Pathways has already been granted 8 patents in the United States, Hong Kong, Germany and UK.
The company has been using the form A hydrate in COMP360, the company’s synthesized psilocybin formulation being developed for psilocybin therapy in treatment-resistant depression.
This goes down as the fourth patent COMPASS Pathways has received from the US Patent and Trademark Office. The new patent was granted on October 19 as US patent Number 11,149,044.
The new patent covers Cybin’s composition claims to an alternative crystalline psilocybin, pharmaceutical formulations comprising of crystalline psilocybin and methods of treating major depressive disorder with crystalline psilocybin.
“We are focused on developing the best therapies and bringing them to patients who are not helped by existing therapies in mental health care. With each new patent grant, the USPTO is recognizing our innovation, enabling us to continue to do the highest quality clinical research and to broaden our portfolio of evidence-based therapies for patients who urgently need better options,” said the company’s CEO, George Goldsmith.